Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial - The Lancet Oncology
2020 ASCO Annual Meeting - Conference Program - Clin Onc 2020 - 22991 | CCO
Landmark trials in Ovarian Cancer | PPT
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
Recurrent High Grade Serous Ovarian Cancer Management - Ovarian Cancer - NCBI Bookshelf
PPT - AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4) PowerPoint Presentation - ID:1402011
Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer Thomas J. Herzog, MD Director, Division of Gynecologic Oncology. - ppt download
Effect of HIPEC according to HRD/BRCAwt genomic profile in stage III ovarian cancer: Results from the phase III OVHIPEC trial - Koole - 2022 - International Journal of Cancer - Wiley Online Library
Frontiers | Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer
Secondary cytoreductive surgery for recurrent ovarian cancer improves overall survival - BJMO
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
A trial looking at surgery for ovarian cancer that has come back (DESKTOP 3, ENGOT ov20) | Cancer Research UK
JGO :: Journal of Gynecologic Oncology
Advances in the Management of Platinum-Sensitive Relapsed Ovarian Cancer | Journal of Clinical Oncology
PPT - An Oncology Exchange Activity PowerPoint Presentation, free download - ID:5600388
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
A trial looking at surgery for ovarian cancer that has come back (DESKTOP 3, ENGOT ov20) | Cancer Research UK
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
PDF) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
Shannon Westin, MD, MPH, FASCO on X: "This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent # ovariancancer - DESKTOP III and SOC -1 #ASCO20 #SGOatASCO #gyncsm https://t.co/pHGWklYWKs" /
Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option - ScienceDirect
